Using AI/ML (Artificial Intelligence/Machine Learning) to screen highly optimized small molecules targeting specific receptors is a burgeoning field that promises to greatly accelerate drug discovery and development. A recent article in Nature Medicine (https://doi.org/10.1038/s41591-023-02361-0) describes the current state of the field.
Only six companies are listed as having drugs in clinical trials designed using AI/MI. Recently, one such company, Recursion, announced a $50 million Investing by NVIDIA (https://ir.recursion.com/news-releases/news-release-details/recursion-announce-collaboration-and-50-million-investment). Recursion spent itself recently $87.5 million The acquisition of two AI/ML drug discovery companies (https://ir.recursion.com/news-releases/news-release-details/recursion-enters-agreements-acquire-cyclica-and-valence-bolster).
d said Harry LanderSybleu Chief Scientific Officer. “We expect it to add significant value to the company as both a scientific and strategic asset.”
“The field is extraordinarily dynamic right now and consolidation is happening – it’s typical when a completely new technology is introduced with the potential to change the status quo,” he said. Joseph FineSybleu CEO.
About Sybleu Corporation
SYBLEU INC. (OTC PINK: SYBE) is a biotechnology company focused on human and animal health therapies, medical devices, and clinical diagnostics. Our strategy is to acquire intellectual property and establish strategic partnerships to develop technologies in the market. SYBLEU is currently exploring opportunities in veterinary therapeutics, diagnostics and medical devices. Additional information on SYBLEU is available at http://www.sybleu.com
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the impact of government regulations, competition and other material risks.
contact information:
Mr. Joseph G
Chairman of the Board and Chief Executive Officer
+ 1,800,807,4631 tel
Email: (email protected)voice.com
SOURCE Sybleu Inc.
